Key Takeaways
- Miles Wang is leaving OpenAI to start a new AI drug discovery company.
- The startup is reportedly valued at $2 billion, with plans to raise $200 million.
- Wang’s venture aims to find new uses for existing drugs.
- Several other OpenAI researchers may join him in this new endeavor.
Wang’s New Venture
Miles Wang, a researcher at OpenAI known for his work in AI-driven scientific discovery, is preparing to launch a startup focused on AI drug discovery. This new company is expected to be valued at around $2 billion, with Wang seeking to raise approximately $200 million to kickstart operations. Discussions are ongoing, and Lightspeed is reportedly in talks to lead the funding round.
Funding Details
While Wang has challenged the reported funding figures and specifics about the company, he has not provided alternative numbers. The interest from investors highlights a growing trend in utilizing AI to advance life sciences. For instance, Chai Discovery recently secured $400 million at a valuation of $3.8 billion, while Isomorphic Labs, a spinout from Google DeepMind, raised $2.1 billion in May for similar initiatives.
Focus on Existing Drugs
Wang’s startup may concentrate on developing AI models that identify new applications for existing drugs, including those that have previously failed in clinical trials. This approach could lead to quicker revenue generation, as these drugs have already undergone safety testing.
Wang’s Background
Wang joined OpenAI in 2024 after leaving Harvard, where he was pursuing a degree in computer science. His experience at OpenAI includes co-authoring research papers that explore how AI can enhance scientific discovery processes.